Table 2.

Relative Risks Of Clinical Outcomes According To Treatment Assignment with Folic acid/Vitamin B₆/Vitamin B₁₂ versus Placebo.

Outcome	Active N=2721	Placebo N=2721	Relative risk* (95% CI)	P value
	No of Patients (%)
Combined Major Cardiovascular Disease†	406 (14.9)	390 (14.3)	1.03 (0.90–1.19)	0.65
Myocardial Infarction	65 (2.4)	74 (2.7)	0.87 (0.63–1.22)	0.42
Stroke	79 (2.9)	69 (2.5)	1.14 (0.82–1.57)	0.44
Ischemic‡	69 (2.5)	62 (2.3)	1.10 (0.78–1.56)	0.57
Hemorrhagic‡	10 (0.4)	6 (0.2)	1.65 (0.60–4.53)	0.33
Coronary Revascularization§	253 (9.3)	255 (9.4)	0.99 (0.83–1.17)	0.87
Coronary Artery Bypass Grafting||	87 (3.2)	98 (3.6)	0.88 (0.66–1.17)	0.38
Percutaneous Coronary Intervention||	192 (7.1)	177 (6.5)	1.08 (0.88–1.33)	0.46
Cardiovascular death	96 (3.5)	94 (3.5)	1.01 (0.76–1.35)	0.93
Myocardial infarction, stroke, and cardiovascular death	205 (7.5)	211 (7.8)	0.96 (0.80–1.17)	0.72
Total coronary heart disease#|	283 (10.4)	280 (10.3)	1.00 (0.85–1.18)	0.96
Total mortality	250 (9.2)	256 (9.4)	0.97(0.81–1.15)	0.73

^*Estimated from Cox proportional hazards models that adjusted for age and randomized treatment assignment to vitamin E., vitamin C, and beta-carotene.

^†The primary outcome is defined as a composite endpoint comprising the first of any of these events: non-fatal myocardial infarction, stroke, coronary revascularization procedures (coronary artery bypass grafting or percutaneous coronary intervention), and cardiovascular mortality.

^‡Stroke type was unknown for 1 woman in the placebo group.

^§Composite endpoint comprised of the first coronary artery bypass grafting or percutaneous coronary intervention.

^||Includes all incident coronary artery bypass grafting operations and percutaneous coronary intervention respectively.

^#|Composite endpoint comprised of the first of any of these events: non-fatal myocardial infarction, coronary revascularization procedures (coronary artery bypass grafting or percutaneous coronary intervention), and coronary heart disease death.